TY - JOUR
T1 - Radiation dosimetry of [18F](N-methyl)benperidol as determined by whole-body PET imaging of primates
AU - Moerlein, Stephen M.
AU - Perlmutter, J. S.
AU - Cutler, P. D.
AU - Welch, M. J.
N1 - Funding Information:
The authors thank Dr. J. Eichling and Dr. F. Dehdashti for helpful discussions. We also thank L. Lich and J. Carl for expert technical assistance with the animal studies, J. Hood and J. Giovanni for data processing, and D. Ficke and W. Murgewu for radioisotope production. This work was supported by NIH FIRST Award lR29N526788 (S.M.M.), NIH Grants R01NS31001, ROlNS32318, and 2POlHL 1385132, as well as rhe generous support of the Dana Clinical Hypothesis Resenrch Program of the Charles A. Dana Foundation, rhe McDonnell Center for the Study of Higher Brain Function, the Greater St. Louis Chapter of the American Parkinson’s Disease Association, and the Barbara B Sam Murphy Fund.
PY - 1997/5
Y1 - 1997/5
N2 - Radiation absorbed doses due to IV administration of [18FI(N-methyl)benperidol ([18F]NMB) were estimated by whole body PET imaging of nonhuman primates. Time-activity curves were obtained for nine compartments (striatum, eyes, heart, lungs, liver, gallbladder, intestines, kidneys, bladder) by using dynamic PET scans of three different baboons given the radiotracer. These time-activity curves were used to calculate the residence times of radioactivity in these tissues. Human absorbed dose estimates were calculated using the updated MIRDOSE 3 S values and assuming the same biodistribution. Based on an average of three studies, the critical organs were the lower large intestine, gallbladder, and liver, receiving doses of 585, 281, and 210 mrad/mCi, respectively, The brain received a dose of 13 mrad/mCi; other organs received doses between 32-77 mrad/mCi. These results indicate that up to 8.5 mCi of [18F]NMB can be safely administered to human subjects for PET studies of D2 receptor binding.
AB - Radiation absorbed doses due to IV administration of [18FI(N-methyl)benperidol ([18F]NMB) were estimated by whole body PET imaging of nonhuman primates. Time-activity curves were obtained for nine compartments (striatum, eyes, heart, lungs, liver, gallbladder, intestines, kidneys, bladder) by using dynamic PET scans of three different baboons given the radiotracer. These time-activity curves were used to calculate the residence times of radioactivity in these tissues. Human absorbed dose estimates were calculated using the updated MIRDOSE 3 S values and assuming the same biodistribution. Based on an average of three studies, the critical organs were the lower large intestine, gallbladder, and liver, receiving doses of 585, 281, and 210 mrad/mCi, respectively, The brain received a dose of 13 mrad/mCi; other organs received doses between 32-77 mrad/mCi. These results indicate that up to 8.5 mCi of [18F]NMB can be safely administered to human subjects for PET studies of D2 receptor binding.
KW - D2 receptor ligands
KW - Dosimetry
KW - PET
KW - Positron emission tomography
KW - [F[N-methyl)benperidol
KW - [F]NMB
UR - http://www.scopus.com/inward/record.url?scp=0030611041&partnerID=8YFLogxK
U2 - 10.1016/S0969-8051(97)00042-5
DO - 10.1016/S0969-8051(97)00042-5
M3 - Article
C2 - 9257329
AN - SCOPUS:0030611041
SN - 0969-8051
VL - 24
SP - 311
EP - 318
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
IS - 4
ER -